Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Spinal Muscular Atrophy (SMA) Overview | 10 | 1 |
| Therapeutics Development | 11 | 2 |
| Pipeline Products for Spinal Muscular Atrophy (SMA) Overview | 11 | 1 |
| Pipeline Products for Spinal Muscular Atrophy (SMA) Comparative Analysis | 12 | 1 |
| Spinal Muscular Atrophy (SMA) Therapeutics under Development by Companies | 13 | 2 |
| Spinal Muscular Atrophy (SMA) Therapeutics under Investigation by Universities/Institutes | 15 | 1 |
| Spinal Muscular Atrophy (SMA) Pipeline Products Glance | 16 | 3 |
| Late Stage Products | 16 | 1 |
| Clinical Stage Products | 17 | 1 |
| Early Stage Products | 18 | 1 |
| Spinal Muscular Atrophy (SMA) Products under Development by Companies | 19 | 1 |
| Spinal Muscular Atrophy (SMA) Products under Investigation by Universities/Institutes | 20 | 1 |
| Spinal Muscular Atrophy (SMA) Companies Involved in Therapeutics Development | 21 | 16 |
| Astellas Pharma Inc. | 21 | 1 |
| AveXis, Inc. | 22 | 1 |
| Bio Blast Pharma Ltd. | 23 | 1 |
| Cytokinetics, Inc. | 24 | 1 |
| F. Hoffmann-La Roche Ltd. | 25 | 1 |
| Genethon | 26 | 1 |
| Genzyme Corporation | 27 | 1 |
| Ionis Pharmaceuticals, Inc. | 28 | 1 |
| Neurodyn Inc. | 29 | 1 |
| Neurotune AG | 30 | 1 |
| Novartis AG | 31 | 1 |
| Paratek Pharmaceuticals, Inc. | 32 | 1 |
| RaNA Therapeutics, Inc. | 33 | 1 |
| Sarepta Therapeutics, Inc. | 34 | 1 |
| Voyager Therapeutics, Inc. | 35 | 1 |
| WAVE Life Sciences Ltd. | 36 | 1 |
| Spinal Muscular Atrophy (SMA) Therapeutics Assessment | 37 | 9 |
| Assessment by Monotherapy Products | 37 | 1 |
| Assessment by Target | 38 | 2 |
| Assessment by Mechanism of Action | 40 | 2 |
| Assessment by Route of Administration | 42 | 2 |
| Assessment by Molecule Type | 44 | 2 |
| Drug Profiles | 46 | 55 |
| AAD-2004 Drug Profile | 46 | 1 |
| ALB-111 Drug Profile | 47 | 1 |
| Antisense Oligonucleotide to Activate SMN2 for Spinal Muscular Atrophy Drug Profile | 48 | 1 |
| Antisense Oligonucleotides for Spinal Muscular Atrophy Drug Profile | 49 | 1 |
| AVXS-101 Drug Profile | 50 | 3 |
| azithromycin Drug Profile | 53 | 1 |
| CK-2127107 Drug Profile | 54 | 4 |
| Gene Therapy to Activate SMN for Spinal Muscular Atrophy Drug Profile | 58 | 1 |
| Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy Drug Profile | 59 | 1 |
| Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy Drug Profile | 60 | 1 |
| LMI-070 Drug Profile | 61 | 1 |
| ND-602 Drug Profile | 62 | 1 |
| NT-1654 Drug Profile | 63 | 1 |
| nusinersen Drug Profile | 64 | 6 |
| olesoxime Drug Profile | 70 | 5 |
| Oligonucleotide to Activate SMN2 for Spinal Muscular Atrophy Drug Profile | 75 | 1 |
| Oligonucleotides to Activate SMN2 for Spinal Muscular Atrophy Drug Profile | 76 | 1 |
| PMO-25 Drug Profile | 77 | 1 |
| PTKSMA-1 Drug Profile | 78 | 1 |
| RG-7800 Drug Profile | 79 | 2 |
| RG-7916 Drug Profile | 81 | 1 |
| Small Molecules for Central Nervous System Disorders Drug Profile | 82 | 1 |
| Small Molecules for Spinal Muscular Atrophy Drug Profile | 83 | 1 |
| Small Molecules to Activate SMN2 for Spinal Muscular Atrophy Drug Profile | 84 | 1 |
| Small Molecules to Activate SMN2 for Spinal Muscular Atrophy Drug Profile | 85 | 1 |
| Small Molecules to Activate Survival Motor Neuron Protein for Spinal Muscular Atrophy Drug Profile | 86 | 1 |
| Small Molecules to Activate Troponin for Non-Neuromuscular and Neuromuscular Disorders Drug Profile | 87 | 1 |
| Small Molecules to Inhibit GSK-3 for Spinal Muscular Atrophy Drug Profile | 88 | 1 |
| tirasemtiv Drug Profile | 89 | 11 |
| VYSMN-101 Drug Profile | 100 | 1 |
| Spinal Muscular Atrophy (SMA) Dormant Projects | 101 | 2 |
| Spinal Muscular Atrophy (SMA) Discontinued Products | 103 | 1 |
| Spinal Muscular Atrophy (SMA) Product Development Milestones | 104 | 11 |
| Featured News &Press Releases | 104 | 1 |
| Apr 21, 2016: Ionis Pharmaceuticals Reports Data Update from Nusinersen Phase 2 Study in Infants with Spinal Muscular Atrophy and Reviews Neurological Disease Franchise | 104 | 1 |
| Mar 31, 2016: Ionis Pharmaceuticals Advances Nusinersen in the Ongoing SHINE Study in Patients with SMA | 105 | 1 |
| Mar 23, 2016: RaNA Therapeutics Presents Data on Advances in RNA Therapy Targeting Spinal Muscular Atrophy | 105 | 1 |
| Jan 12, 2016: Ionis Pharmaceuticals Completes Target Enrollment for Nusinersen Phase 3 Study, CHERISH, in Children with Spinal Muscular Atrophy | 106 | 1 |
| Jan 07, 2016: Spinal Muscular Atrophy Program Advances with Additional Product Candidate Entering Clinical Development | 106 | 1 |
| Jan 04, 2016: Cytokinetics Announces Start Of Phase 2 Clinical Trial Of Ck-2127107 In Patients With Spinal Muscular Atrophy | 107 | 1 |
| Oct 15, 2015: Isis Pharmaceuticals Initiates SHINE Study to Provide ISIS-SMN for Patients With SMA Who Have Completed the Phase 3 ENDEAR and CHERISH Studies | 108 | 1 |
| Oct 04, 2015: Phase 2 Data from Spinal Muscular Atrophy Program Presented at the 20th International Annual Congress of the World Muscle Society | 109 | 1 |
| Jul 14, 2015: Isis Pharmaceuticals Earns $2.15M for Advancing ISIS-SMN in Children With Spinal Muscular Atrophy | 110 | 1 |
| Jun 22, 2015: BioBlast Announces Positive Preclinical Proof-Of-Concept Results Of Its Novel Read- through Platform in Spinal Muscular Atrophy | 110 | 1 |
| Jun 22, 2015: Isis Pharmaceuticals Reports Data from ISIS-SMN Rx in Children with Spinal Muscular Atrophy | 111 | 1 |
| Jun 19, 2015: Cytokinetics Presents Results From Phase I Studies Of Ck-2127107 | 112 | 1 |
| Jun 18, 2015: BioBlast Pharma to Present Preclinical Proofs of Concept in Spinal Muscular Atrophy at Two Leading Scientific Meetings in June | 112 | 1 |
| Jun 11, 2015: Isis Pharmaceuticals Reports Data From ISIS-SMN Rx Phase 2 Study in Infants With Spinal Muscular Atrophy | 113 | 1 |
| Apr 20, 2015: Phase 1 Data from Spinal Muscular Atrophy Program to be Presented at the 2015 American Academy of Neurology Annual Meeting | 114 | 1 |
| Appendix | 115 | 2 |
| Methodology | 115 | 1 |
| Coverage | 115 | 1 |
| Secondary Research | 115 | 1 |
| Primary Research | 115 | 1 |
| Expert Panel Validation | 115 | 1 |
| Contact Us | 115 | 1 |
| Disclaimer | 116 | 1 |